DE69310734D1 - PEPTID FOR THE STIMULATION OF CYTOTOIC T LYMPHOCYTES SPECIFIC FOR HEPATITIS C VIRUS - Google Patents
PEPTID FOR THE STIMULATION OF CYTOTOIC T LYMPHOCYTES SPECIFIC FOR HEPATITIS C VIRUSInfo
- Publication number
- DE69310734D1 DE69310734D1 DE69310734T DE69310734T DE69310734D1 DE 69310734 D1 DE69310734 D1 DE 69310734D1 DE 69310734 T DE69310734 T DE 69310734T DE 69310734 T DE69310734 T DE 69310734T DE 69310734 D1 DE69310734 D1 DE 69310734D1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- ctl
- hepatitis
- recognize
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000000638 stimulation Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 238000011725 BALB/c mouse Methods 0.000 abstract 1
- 241001227713 Chiron Species 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The cytotoxic T cell response to the protein encoded by the NS5 region of hepatitis C virus was determined using 28 peptides from NS5 which were selected by an amphipathicity algorithm as candidates for T cell epitopes. In BALB/c mice, a single relatively conserved epitope represented by a 16-residue synthetic peptide was presented by Dd class I major histocompatibility complex (MHC) molecules to conventional CD4-CD8+ CTL. An exemplary peptide, which represents amino acid residues 2422-2437 of the polyprotein of the Chiron HCV1 isolate, had the amino acid sequence MSYSWTGALVTPCAAE [SEQ ID NO: 1]. A CTL line specific for this peptide recognized the two known natural variants of this NS5 sequence, each with conservative substitutions. Thus, CTL can recognize the product of the HCV NS5 gene, the probable RNA polymerase, in association with class I MHC molecules on model target cells and may recognize the same epitope on hepatocytes or any other cells infected with the virus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/894,063 US5980899A (en) | 1992-06-10 | 1992-06-10 | Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells |
| PCT/US1993/005434 WO1993025575A1 (en) | 1992-06-10 | 1993-06-10 | Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69310734D1 true DE69310734D1 (en) | 1997-06-19 |
| DE69310734T2 DE69310734T2 (en) | 1998-01-15 |
Family
ID=25402543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69310734T Expired - Fee Related DE69310734T2 (en) | 1992-06-10 | 1993-06-10 | PEPTID FOR THE STIMULATION OF CYTOTOIC T LYMPHOCYTES SPECIFIC FOR HEPATITIS C VIRUS |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5980899A (en) |
| EP (1) | EP0644894B1 (en) |
| JP (1) | JP3510249B2 (en) |
| AT (1) | ATE153031T1 (en) |
| AU (1) | AU669193B2 (en) |
| CA (1) | CA2135278C (en) |
| DE (1) | DE69310734T2 (en) |
| DK (1) | DK0644894T3 (en) |
| ES (1) | ES2104156T3 (en) |
| GR (1) | GR3024462T3 (en) |
| WO (1) | WO1993025575A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582968A (en) * | 1990-02-16 | 1996-12-10 | United Biomedical, Inc. | Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis |
| US5639594A (en) * | 1990-02-16 | 1997-06-17 | United Biomedical, Inc. | Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| AU773000C (en) * | 1994-07-27 | 2004-10-07 | Csl Limited | Polyepitope vaccines |
| CA2195642A1 (en) * | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
| US5767233A (en) * | 1995-05-12 | 1998-06-16 | Schering Corporation | Soluble cleavable substrates of the hepatitis C virus protease |
| GB9618119D0 (en) | 1996-08-30 | 1996-10-09 | Univ Southampton | Adjuvants for use in vaccines |
| EP1037974B1 (en) | 1997-12-11 | 2007-10-03 | SmithKline Beecham Corporation | Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds |
| WO2001021189A1 (en) * | 1999-07-19 | 2001-03-29 | Epimmune Inc. | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| BR0108210A (en) | 2000-02-04 | 2002-10-22 | Univ Duke | Vaccine against human immunodeficiency virus |
| WO2001072331A1 (en) * | 2000-03-31 | 2001-10-04 | Vaccine Chip Technology Aps | Immunostimulating properties of a fragment of tgf-beta |
| ATE502952T1 (en) * | 2000-09-01 | 2011-04-15 | Epimmune Inc | HLA-BINDING PEPTIDES AND THEIR USES |
| US7326536B2 (en) * | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
| FR2828934B1 (en) * | 2001-08-27 | 2004-08-13 | Inst Nat Sante Rech Med | TEST OF CELL IMMUNITY BY FIXED PEPTIDES ON SOLID SUPPORT |
| EP1357127A1 (en) * | 2002-04-10 | 2003-10-29 | Immusystems GmbH | Hepatitis c virus epitopes specific for cd4+ t-cell lymphocytes |
| CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| CA2624153A1 (en) * | 2005-09-29 | 2007-04-12 | The Scripps Research Institute | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family |
| CA2658227A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
| EP3765075A4 (en) * | 2018-03-16 | 2021-12-08 | The Governors of the University of Alberta | Hepatitis c virus peptide compositions and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861588A (en) * | 1985-02-05 | 1989-08-29 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| IE62868B1 (en) * | 1987-11-18 | 1995-03-08 | Chiron Corp | Hepatitis C virus |
| CA2047792C (en) * | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
-
1992
- 1992-06-10 US US07/894,063 patent/US5980899A/en not_active Expired - Fee Related
-
1993
- 1993-06-10 AT AT93915244T patent/ATE153031T1/en not_active IP Right Cessation
- 1993-06-10 EP EP93915244A patent/EP0644894B1/en not_active Expired - Lifetime
- 1993-06-10 JP JP50165694A patent/JP3510249B2/en not_active Expired - Fee Related
- 1993-06-10 CA CA002135278A patent/CA2135278C/en not_active Expired - Fee Related
- 1993-06-10 WO PCT/US1993/005434 patent/WO1993025575A1/en active IP Right Grant
- 1993-06-10 AU AU45300/93A patent/AU669193B2/en not_active Ceased
- 1993-06-10 ES ES93915244T patent/ES2104156T3/en not_active Expired - Lifetime
- 1993-06-10 DE DE69310734T patent/DE69310734T2/en not_active Expired - Fee Related
- 1993-06-10 DK DK93915244.3T patent/DK0644894T3/en active
-
1997
- 1997-08-14 GR GR970402100T patent/GR3024462T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0644894B1 (en) | 1997-05-14 |
| ES2104156T3 (en) | 1997-10-01 |
| ATE153031T1 (en) | 1997-05-15 |
| US5980899A (en) | 1999-11-09 |
| AU4530093A (en) | 1994-01-04 |
| CA2135278C (en) | 2005-08-09 |
| CA2135278A1 (en) | 1993-12-23 |
| JPH08501282A (en) | 1996-02-13 |
| WO1993025575A1 (en) | 1993-12-23 |
| DE69310734T2 (en) | 1998-01-15 |
| DK0644894T3 (en) | 1997-12-08 |
| GR3024462T3 (en) | 1997-11-28 |
| AU669193B2 (en) | 1996-05-30 |
| JP3510249B2 (en) | 2004-03-22 |
| EP0644894A1 (en) | 1995-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69310734T2 (en) | PEPTID FOR THE STIMULATION OF CYTOTOIC T LYMPHOCYTES SPECIFIC FOR HEPATITIS C VIRUS | |
| Rottier et al. | Predicted membrane topology of the coronavirus protein E1 | |
| KR960704923A (en) | Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS | |
| Kanai et al. | Poly (U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicase | |
| Mizushima et al. | Analysis of N-terminal processing of hepatitis C virus nonstructural protein 2 | |
| Kurokohchi et al. | Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region | |
| Hirowatari et al. | Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector | |
| IL133056A0 (en) | A polypeptide containing an immunogenic portion of a m tuberculosis antigen a variant thereof pharmaceutical compositions vaccines and kits containing same | |
| SE9004010D0 (en) | VIRAL MEDICINE | |
| NZ319786A (en) | HCV NS3 protein fragments with helicase activity and improved solubility | |
| CA2389206A1 (en) | Activation of hcv-specific t cells | |
| KR940703860A (en) | Novel human Kunizin protease inhibitors and variants thereof (A NOVEL HUMAN KUNITZ-TYPE PROTEASE INHIBITOR AND VARIANTS THEREOF) | |
| JP2007516696A5 (en) | ||
| KR900016261A (en) | Poison Pox Polypeptide and Genetic Expression | |
| EP0544838A4 (en) | Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines | |
| Kane et al. | Cytolytic T-lymphocyte response to isolated class IH–2 proteins and influenza peptides | |
| MY135991A (en) | A vaccine-induced hepatits b viral strain and uses thereof | |
| ATE166390T1 (en) | ANTI-CAT IMMUNODEFICIENCY VIRUS (FIV) VACCINES | |
| US5026686A (en) | Antiviral peptides | |
| KR880000579A (en) | Method of producing VeriCella-Joster virus | |
| NO20006456L (en) | A mutant human hepatitis B viral strain and uses thereof | |
| CA2062097A1 (en) | Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus | |
| Pearson et al. | Predicted Membrane Topology of the Coronavirus Protein El | |
| PT89041A (en) | Purified hepatitis C virus - and associated nucleic acids and polypeptide(s) | |
| TH44158A3 (en) | Hepatitis B strains induced by vaccines and inactivation of those strains. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |